Orphan Therapeutics

Call
3 Werner Way Ste 300
Lebanon, NJ 08833

Orphan Therapeutics is a privately held drug development company founded in 2003, focused on developing and obtaining regulatory approval for terlipressin to treat Hepatorenal Syndrome (HRS) type 1 in the United States. The company licensed its development rights for terlipressin to Ikaria, which was later acquired by Mallinckrodt, and continued to support the FDA approval process.

In September 2022, the FDA approved Terlivaz (terlipressin injection) to improve kidney function in adults with Hepatorenal Syndrome, marking a significant milestone for Orphan Therapeutics. The company remains committed to advancing treatments for rare diseases and improving patient outcomes.

Generated from the website

Own this business?
See a problem?

You might also like

United StatesNew JerseyLebanonOrphan Therapeutics